Helix Biomedics LLC | Boynton Beach, FL
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each participant will receive open-label amlitelimab from Week 24 onwards. The purpose of this study is to evaluate long-term safety, tolerability, and efficacy of amlitelimab for the treatment of adult participants with moderate-to-severe asthma who have previously been enrolled and completed the treatment period of the parent study. The study duration will be up to 156 weeks. The treatment duration will be up to 144 weeks. The number of visits will be 18.
Full description
The duration of the study for each participant will be up to 156 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
For female participants:
Exclusion criteria
Participants are excluded from the study if any of the following criteria apply:
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Primary purpose
Allocation
Interventional model
Masking
380 participants in 2 patient groups
Loading...
Central trial contact
Trial transparency email recommended (Toll free number for US & Canada)
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal